Activation of alternative HER receptors mediates resistance to EGFR tyrosine kinase inhibitors in breast cancer cells

A.Kong; V.Calleja; P.Leboucher; A.Harris; P.Parker; B.Larijani

首页> 外文期刊>European Journal of Cancer Supplements >Activation of alternative HER receptors mediates resistance to EGFR tyrosine kinase inhibitors in breast cancer cells

【24h】

Activation of alternative HER receptors mediates resistance to EGFR tyrosine kinase inhibitors in breast cancer cells

机译：替代性HER受体的激活介导了乳腺癌细胞对EGFR酪氨酸激酶抑制剂的耐药性

获取原文

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

著录项
引文网络
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements》 |2008年第9期|共1页
作者
A.Kong; V.Calleja; P.Leboucher; A.Harris; P.Parker; B.Larijani;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. 485 POSTER Activation of alternative HER receptors mediates resistance to EGFR tyrosine kinase inhibitors in breast cancer cells [J] . A.Kong, V.Calleja, P.Leboucher, European Journal of Cancer Supplements . 2008,第12期

机译：485海报替代性HER受体的激活介导了乳腺癌细胞对EGFR酪氨酸激酶抑制剂的耐药性
2. 485 POSTER Activation of alternative HER receptors mediates resistance to EGFR tyrosine kinase inhibitors in breast cancer cells [J] . A.Kong, V.Calleja, P.Leboucher, European Journal of Cancer Supplements . 2008,第12期

机译：485海报替代性HER受体的激活介导了乳腺癌细胞对EGFR酪氨酸激酶抑制剂的耐药性
3. Activation of alternative HER receptors mediates resistance to EGFR tyrosine kinase inhibitors in breast cancer cells [J] . A.Kong, V.Calleja, P.Leboucher, European Journal of Cancer Supplements . 2008,第9期

机译：替代性HER受体的激活介导了乳腺癌细胞对EGFR酪氨酸激酶抑制剂的耐药性
4. Profiling and Cross-Talk of Tyrosine Phosphorylation with Lysine Acetylation and Succinylation in Tyrosine Kinase Inhibitor Resistant Breast Cancer Cells [C] . Hongbo Gu, Erik J. Soderblom, J. Will Thompson, ASMS Conference on Mass Spectrometry and Allied Topics . 2014

机译：酪氨酸激酶抑制剂抗性乳腺癌细胞赖氨酸乙酰化和琥珀酸抗蛋白酶磷酸化的分析和串扰
5. Receptor tyrosine kinase-like orphan receptor-1 (ROR1) expression in breast cancer stem cells can be targeted for anti-cancer-stem-cell therapy [D] . Liu, Grace. 2015

机译：乳腺癌干细胞中受体酪氨酸激酶样孤儿受体1（ROR1）的表达可用于抗癌干细胞治疗
6. HER2 Oncogenic Function Escapes EGFR Tyrosine Kinase Inhibitors via Activation of Alternative HER Receptors in Breast Cancer Cells [O] . Anthony Kong, Véronique Calleja, Pierre Leboucher, 2008

机译：HER2致癌功能通过激活乳腺癌细胞中替代性HER受体逃逸了EGFR酪氨酸激酶抑制剂
7. HER2 oncogenic function escapes EGFR tyrosine kinase inhibitors via activation of alternative HER receptors in breast cancer cells. [O] . Kong, A, Calleja, V, Leboucher, P, 2008

机译：HER2致癌功能通过激活乳腺癌细胞中替代性HER受体而逃脱EGFR酪氨酸激酶抑制剂。
8. Systematic Reviews on Selected Pharmacogenetic Tests for Cancer Treatment: CYP2D6 for Tamoxifen in Breast Cancer, KRAS for anti-EGFR antibodies in Colorectal Cancer, and BCR-ABL1 for Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia. Technology Assessment Report [R] . Terasawa, T., Dahabreh, I., Castaldi, P. J., 2010

机译：针对癌症治疗的选定药物遗传学测试的系统评价：CYp2D6用于乳腺癌中的他莫昔芬，KRas用于结肠直肠癌中的抗EGFR抗体，以及BCR-aBL1用于慢性髓性白血病中的酪氨酸激酶抑制剂。技术评估报告

Activation of alternative HER receptors mediates resistance to EGFR tyrosine kinase inhibitors in breast cancer cells

著录项

引文网络

相似文献

相关主题

期刊订阅